AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$STVN

MOREL DONALD E JR purchased $327K of STVN

MOREL DONALD E JR purchased 25,000 shares of Stevanato Group S.p.A. (STVN) at $13.07 ($0.33M total) on 2026-11-06.

Original reporting
SEC EDGAR · MOREL DONALD E JR
Published Nov 10, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$STVN
Bullish
high confidence
Mentioned
$STVN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNBullishLow
01

Why it matters

Director's purchase adds modest confidence signal but unlikely to move price significantly.

02

Market read

Primary insider purchase filing; low materiality due to small size.

03

What to watch

Small transaction size relative to market cap limits impact.

Relevance 5/10Novelty 4/10Timing: filing date 2026-11-10

Background

SEC Form 4 filing discloses insider transaction for Stevanato Group.

Company-level read

Ticker impact

$STVNBullishHigh confidence
Context

Director MOREL DONALD E JR bought 25,000 shares for $326,750, increasing his stake to 62,424 shares.

Expected impact

likely slight upward pressure as market prices in insider buying

Evidence & confidence

Form 4 filing is a primary source; purchase size is modest but director-level buying is viewed positively.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

Insider purchase may be routine portfolio rebalancing, not a strong signal.

Key entities

  • company
    Stevanato Group S.p.A.

    Italian medical device manufacturer listed on NYSE as STVN.

  • person
    MOREL DONALD E JR

    Director of Stevanato Group.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

STVN insider trading history →

Related articles

$STVNHighAI 8/10

Stevanato Group Q3 Earnings Call Highlights

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

finance.yahoo.com
$STVNMed

Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

finance.yahoo.com
$STVNMed

Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8%

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

finance.yahoo.com
$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q3 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

SEC EDGAR 6-K
HighAI 8/10

Why is Stevanato stock plunging today?

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.

investing.com